Actavis develops a solid dosage manufacturing and packing facility at its Manati site in Puerto Rico.
The Puerto Rico Industrial Development Company (PRIDCo) and Actavis announced that the company will develop a solid dosage manufacturing and packing facility at its Manati site and expand its current hormone production in Fajardo.
Actavis is investing $48 million and has committed to create up to 300 new jobs over a 36-month period; it has already has created 100 jobs. The investment will allow the company to bring new lines of generic, brand, and biosimilar products. When the expansion is completed, Actavis will have 700 employees in Puerto Rico.
All plans are expected to be complete by 2016.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.